It’s been quiet on the forum regarding this company, but it would be nice to hear some thoughts on it in something other than the other national language [Swedish] via a translator. We are talking about a Swedish pharmaceutical company developing a treatment for nail fungus. Their current drug candidate, MOB-015, successfully cleared Phase 3 and received the green light in several European countries, and as I understand it, the launch should begin in Sweden early this year. The second round of Phase 3 will be completed in January 2025, after which the US markets will hopefully open up.
There is currently no treatment for nail fungus that is both effective and safe at the same time. The most effective treatment is terbinafine in tablet form, but since it is highly hepatotoxic, it is not an ideal drug. Current topical medications, on the other hand, don’t strain the liver, but the fungus tends to remain in the nail with an unnecessarily high probability. With its new topical drug, Moberg has succeeded in delivering the already known effective terbinafine into and through the nail in high concentrations. Terbinafine administered this way gives the fungus the boot, but blood concentrations do not rise high enough to irritate the liver. In Phase 3, MOB-015 achieved healing in 76% of cases (84% in Europe and 70% in the US), while only 42% with the comparator drug were able to live without nail fungus.
So, the commercialization of a promising drug for an ailment lacking good treatment is now ahead. This isn’t the company’s first rodeo with a new product launch; they have previously successfully developed and launched a product called Kerasal Nail and sold it in 2019 for about 1.4 billion SEK.
What I’ve written should be taken with a grain of salt and there may be errors, as behind this pseudonym is a novice investment enthusiast who knows next to nothing. It would be nice to hear what @Vino_Pino @Rushimato @jerej @Clark_kent, who provide expert commentary on pharmaceutical companies and clearly know the industry better than the average person, think about the company and its future.